BenevolentAI
financial highlights revenue increase across collaboration with a milestone reached related to the second novel target for idiopathic pulmonary spend increase driven by portfolio advancing into later stages of development in particular ben entering adaptive phase i clinical study spend increase increased which is set to plateau bus spend driven predominantly by listing status but expected to maintain at this level | BenevolentAI
Company
Deck Type
Deck date
September 2022
Slide
67 of 74
Similar slides by BenevolentAI
Results
March 2023
Investor Presentation
October 2022
Related slides by other companies
Results
July 2022
Results
August 2021
Investor Presentation
August 2023
Fixed Income
July 2023
Other recent decks by BenevolentAI
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io